The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

This Common Viral Disease Has Plagued Humanity Thousands of Years Longer Than We Thought

Evidence of Hepatitis B has been found in human DNA dating back to the Bronze Age, around 4,500 years ago. We now have proof that it infected humans broadly across Eurasia for millennia, pushing back the earliest evidence we have by thousands of years. Previously, the earliest evidence of Hepatitis B was just 450 years old - and its discovery in a mummified medieval Italian child was only announced earlier this year. A team led by geneticist Eske Wille

The Week in Review: February 9 – February 16, 2018

Friday, February 16, 2018 News Recap: HCV & Heart Disease: Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD. This article examines the evidence for clinical and subclinical cardiovascular diseases in chronic hepatitis c infection, as well as the effect of treatment on cardiovascular outcomes. News from Around the World: NZ: Thousands of Hepatitis C sufferers unaware a cure is within reach. A Hepatitis...

Study reveals the liver’s ‘weak spot’ for hepatitis B virus replication

In a surprising discovery, researchers from the Singapore Immunology Network (SIgN), A*STAR, have found that the liver is the main site of hepatitis B (HBV) replication—not only because it contains material that helps the virus proliferate, but also because most other tissues of the body contain proteins that actively repress HBV replication. "We've been working on this project for a number of years because HBV is very prevalent in Asia," says Ee Chee Ren

The Week in Review: January 19 – January 26, 2018

Friday, January 26, 2018 News Recap: Research and Discoveries: Growing Evidence Shows Hepatitis C Intersects With Other Diseases. As many as three-quarters of individuals with hepatitis C virus (HCV) experience disorders related to the virus beyond the impact on their livers, the National Viral Hepatitis Roundtable estimates. HCV-related kidney disease, depression, skin disorders, lymphoma and other conditions can seriously impact a patient, even wi...

Researchers find sofosbuvir effective in treating Zika-infected individuals

Researchers in California and Brazil said a drug meant to treat and cure hepatitis C could be as effective in treating people infected with Zika, especially in protecting the fetus of an infected pregnant women. Researchers associated with the University of California San Diego and colleagues in Brazil found that in cellular and mice trials, the anti-viral medication Sofosbuvir, brand name Sovaldi, was effective in repairing cells damaged by Zika and bl

The Week in Review: January 12 – January 19, 2018

Friday, January 19, 2018 News Recap: Research & Discoveries: Blood test for early detection of 8 cancers looks promising. Scientists have developed a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. The test, called CancerSEEK, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests wer...

Blood test for early detection of 8 cancers looks promising

Test includes some of the most deadly cancers currently lacking screening tools. Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools now. Many groups are working on liquid biopsy tests, which look for DNA and other things that tumours shed into blood, to try to find cancer before it spreads, when chances of a cure are best. In a study Thu

The Week in Review: December 15 – December 22, 2017

Friday, December 22, 2017 News Recap: Eight Genotypes: Did you know that there are now 8 genotypes and 84 subtypes of HCV that have been identified?  On the one hand this is terrible news; but on the other, a study presented at AASLD 2017 found that Vosevi was effective against them all.  Eight Genotypes and 84 Subtypes of HCV. Telemedicine: Did you know that Project ECHO (Extension for Community Health Outcomes), a fast-growing international tele...

Should uninfected patients accept hepatitis C-infected livers to reduce waiting time?

Study suggests that antiviral drugs may allow safe transplantation of HCV-positive livers into uninfected recipients. A modeling study by Massachusetts General Hospital (MGH) investigators finds that the availability of directly-acting antiviral (DAA) drugs to treat hepatitis C virus (HCV) infection could allow the transplantation of livers from HCV-positive donors into HCV-negative recipients without posing undue risk. The team's report will appear i